Expression of DNMT3b Gene in Myeloma RPMI 8226 Cells and Its Biological Significance.
- Author:
Xiao-Ning WANG
1
;
Jian-Na YAO
1
;
Xiao-Juan WANG
1
;
Chun-Hong SUN
1
;
Cai-Li GUO
1
;
Ying CHEN
1
;
Peng-Cheng HE
2
;
Mei ZHANG
3
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2017;25(5):1431-1435
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the expression of DNMT3b gene in myeloma RPMI8226 cells and its biological significance.
METHODSThe activity of DNA methyltransferase was detected by ELISA, and the expression of DNMT3b in RPMI8226 cells was analyzed by semi-quantitative RT-PCR and real-time fluorescent quantitative PCR. The proliferation and expression of DNMT3b gene in RPMI8226 cells intervened with capecitabine for 24 hours were detected.
RESULTSThe activity of DNMT and expression of DNMT3b in RPMI 8226 cells increased. The proliferation of RPMI8226 cells was inhibited, and the apoptosis occurred in RPMI 8226 cells intervened with capecitabine for 24 hours. The expression level of DNMT3b gene was decreased after being intervened with capecitabine for 24 hours.
CONCLUSIONThe expression level of DNMT3b in myeloma RPMI 8226 cells increase, and capecitabine can inhibit the proliferation of RPMI 8226 and induce apoptosis by inhibiting the expression of DNMT3b gene. Therefore, DNMT3b is expected to be a new target for myeloma therapy.
